Get access

The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists

Authors

  • Vibeke Guldbrand Rasmussen PhD,

    Corresponding author
    1. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
    • Ph.D.; Department of Cardiology, Aarhus University Hospital, Skejby, Brendstrupgaardsvej, 8200 Aarhus N, Denmark
    Search for more papers by this author
  • Karen Østergaard DMSci,

    1. Department of Neurology, Aarhus University Hospital, Denmark
    Search for more papers by this author
    • Erik Dupont MD,

      1. Department of Neurology, Aarhus University Hospital, Denmark
      Search for more papers by this author
      • Relevant conflict of interest/financial disclosures: As research fellow Dr. Rasmussen received financial support from the Danish Heart Foundation and The Danish Parkinson's Disease Association. Dr. Østergaard received research grants from the Danish Medical Research Council, the Lundbeck Foundation, and the Danish Parkinson's disease. Drs. Dupont and Poulsen have no relevant disclosures. Full financial disclosures and author roles can be found in the online version of this article.

    • Steen Hvitfeldt Poulsen DMSci

      1. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark
      Search for more papers by this author

    Abstract

    Objectives:

    Several observational studies suggest an association between treatment with ergoline-derived dopamine agonists and valvular regurgitation. In this article, we present an overview of the literature and conduct a meta-analysis.

    Methods:

    Observational studies addressing the frequency of moderate or severe valvular regurgitation among ergoline-treated patients with Parkinson's disease were considered for a meta-analysis. Pooled risk estimates and the risk of increased pulmonary artery pressure were calculated.

    Results:

    The pooling of data from well-designed observational studies documented that both pergolide (RR = 3.05 [1.71–5.44]) and cabergoline (RR = 6.38 [3.17–12.81]) represent a substantially increased risk of developing moderate to severe valvular regurgitation. In addition, pergolide, but not cabergoline, was associated with an increase in pulmonary artery pressure.

    Conclusions:

    The present meta-analysis confirmed a statistically significant association between pergolide and cabergoline treatment and the risk of moderate to severe valvular regurgitation. An association between bromocriptine and valvular regurgitation cannot be entirely ruled out. © 2011 Movement Disorder Society

    Get access to the full text of this article

    Ancillary